Sign In

Aerocrine: 3.32m EUR in new funds

16 May 2001 10:54
By Tornado Staff

Aerocrine, a Stockholm biotechnology company that patented NIOX, a nitric monitoring product which is the cause of breathing inflammations like asthma, announced a capital increase with the flotation of 2.5 million new shares.

Old shareholders like Investor, the Wallenberg family finance company, and HealthCap Venture, a venture capital fund specialised in biotech companies are underwriting the flotation said to be worth 3.32 million euro along with the new investors 6AP Fonden and Health & Brands.

Related stories
Mucosis wins Wellcome Trust award and backing from current investors
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Big VC rounds for Ganymed and MISSION to fight cancer


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Apr 21€0.0MMedical devices
Apr 14€34.0MSecurity
Apr 14N/AOther Biotechnology & Healthcare
Apr 13N/AInternet services
Apr 13€38.0MMaterials
Apr 12€18.0MEnergy related
Apr 12€6.0MConsumer applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.